TWTheo De Witte

Theo De Witte

*This is an algorithmically generated author record based on publicly available information.

Theo De Witte has a total of 206 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • P-277 Decitabine vs. best supportive care in elderly higher-risk MDS patients with or without monosomal karyotypes: EORTC-LG/GMDS-SG phase III trial 06011

    by M. Lübbert, S. Suciu, A. Hagemeijer, U. Platzbecker, A. Giagounidis, D. Selleslag, U. Germing, H.R. Salih, P. Muus, L. Bogatyreva, et al.

  • LeukemiaNet: A transnational model for cooperative leukemia research.

    by R. Hehlmann, B. Simonsson, M. Baccarani, D. Grimwade, J. Apperley, T. Barbui, M. C. Bene, T. Buchner, T. J. de Witte, R. Foà, et al.

    6556 Background: Leukemia research may be jeopardized by lack of communication structures or fragmentation of study activities, insufficient interaction and underestimation of the problem. Methods: Recognizing that the only way to cure leukemia is by cooperative research, scientists in Europe in 2002, set out to establish an exemplary cooperative network for research in leukemia, the European LeukemiaNet (ELN). At present, ELN integrates 105 national leukemia trial groups and networks, 105 interdisciplinary specialty groups and about 1000 leukemia specialists from 175 institutions. They care for ten thousands of leukemia patients in 33 countries. Results: The most visible results are 1.) those due to the cooperative research projects and trials as reflected by a large number of high impact publications; and 2.) the guidelines and management recommendations for virtually every type of leukemia and interdisciplinary specialty which have lain the groundwork for uniform definitions and standards required for common clinical trials and projects. Conclusions: ELN is a model of transnational cooperation. Working together successfully has created a spirit of cooperation and mutual trust. Due to its structured and long-term cooperation, ELN is likely to have a durable impact on leukemia research in Europe. By promoting cooperation over competition that is necessary for good research, ELN provides a competitive advantage for all participants to the benefit of every patient with leukemia worldwide.

  • Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS

    by Theo de Witte, Stefan Suciu, Gregor Verhoef, Boris Labar, Eric Archimbaud, Carlo Aul, Dominique Selleslag, Augustin Ferrant, Pierre Wijermans, Franco Mandelli, et al.

    This study investigated the feasibility of allogeneic (alloSCT) and autologous stem cell transplantation (ASCT) as postconsolidation therapy for patients with myelodysplastic syndromes (MDSs) or acute myeloid leukemia after MDS. Patients with a histocompatible sibling were candidates for alloSCT and the remaining patients for ASCT. Remission-induction therapy consisted of 1 or 2 courses with idarubicin, cytarabine, and etoposide, followed by one intensive consolidation course with cytarabine and mitoxantrone. Initially, bone marrow cells were used for ASCT. Subsequently, mobilized blood stem cells were used in an attempt to shorten posttransplantation hypoplasia. With a median follow-up of 3.6 years the 184 evaluable patients showed a 4-year survival rate of 26% and a median survival of 13 months. The remission-induction chemotherapy induced complete remission (CR) in 100 patients (54%). The 4-year disease-free survival (DFS) rate was 29% and the median DFS was 12 months. Twenty-eight of 39 patients (72%) with a donor were allografted in CR-1, including 2 patients who underwent transplantation in CR-1 without a consolidation course. Thirty-six of 59 patients (61%) without a donor received ASCT in CR-1. The 4-year DFS rates in the group of patients with or without a donor were 31% and 27%, respectively. The 4-year survival rates from CR were 36% and 33%, respectively. This large prospective study shows the feasibility of both alloSCT and ASCT. This treatment approach leads to a relatively high remission rate, and the majority of patients in remission received the SCT in CR-1. The ongoing study investigates whether this approach is better than treatment with chemotherapy only.


    • 1 December 2000
      • Vol. 96  (12) , 3671-4

    Report of an international working group to standardize response criteria for myelodysplastic syndromes.

    by B D Cheson, J M Bennett, H Kantarjian, A Pinto, C A Schiffer, S D Nimer, B Löwenberg, M Beran, T M De Witte, R M Stone, et al.

    Standardized criteria for assessing response are essential to ensure comparability among clinical trials for patients with myelodysplastic syndromes (MDS). An international working group of experienced clinicians involved in the management of patients with MDS reviewed currently used response definitions and developed a uniform set of guidelines for future clinical trials in MDS. The MDS differ from many other hematologic malignancies in their chronicity and the morbidity and mortality caused by chronic cytopenias, often without disease progression to acute myeloid leukemia. Whereas response rates may be an important endpoint for phase 2 studies of new agents and may assist regulatory agencies in their evaluation and approval processes, an important goal of clinical trials in MDS should be to prolong patient survival. Therefore, these response criteria reflected 2 sets of goals in MDS: altering the natural history of the disease and alleviating disease-related complications with improved quality of life. It is anticipated that the recommendations presented will require modification as more is learned about the molecular biology and genetics of these disorders. Until then, it is hoped these guidelines will serve to improve communication among investigators and to ensure comparability among clinical trials. (Blood. 2000;96:3671-3674)


  • Open Access

    Haematopoietic stem cell transplantation for patients with myelo‐dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

    by Theo De Witte, Jo Hermans, Jaak Vossen, Andrea Bacigalupo, Giovanna Meloni, Niels Jacobsen, Tapani Ruutu, Per Ljungman, Alois Gratwohl, Volker Runde, et al.

    Allogeneic stem cell transplantation from an HLA‐identical sibling donor is a curative treatment option for a young patient with myelodysplastic syndrome, limited by age and lack of sibling donors. Alternative stem cell sources have been used more recently, such as unrelated donors, non‐identical family members or autologous transplants. This analysis of 1378 transplants reported to the European Group for Blood and Marrow Transplantation (EBMT) addresses the outcome of the varying procedures according to the known risk factors. The estimated disease‐free survival (DFS) and estimated relapse risk at 3 years were both 36% for 885 patients transplanted with stem cells from matched siblings. In the multivariate analysis, age and stage of disease had independent prognostic significance for DFS, survival and treatment‐related mortality. Patients transplanted at an early stage of disease had a significantly lower risk of relapse than patients transplanted at more advanced stages. The estimated DFS at 3 years was 25% for the 198 patients with voluntary unrelated donors, 28% for the 91 patients with alternative family donors and 33% for the 126 patients autografted in first complete remission. The non‐relapse mortality was 58% for patients with unrelated donors, 66% for patients with non‐identical family donors and 25% for autografted patients. The relapse rate of 18% was relatively low for patients with non‐identical family donors, 41% for patients with unrelated donors and 55% for patients treated with autologous stem cell transplantation. Both allogeneic and autologous stem cell transplantation have emerged as treatment options for patients with myelodysplastic syndromes. Transplantation with an HLA‐identical sibling donor is the preferred treatment option. Patients without an HLA‐identical sibling donor may be treated with either autologous stem cell transplantation or an alternative donor transplantation. Patients younger than 20 years may be treated with an unrelated donor transplantation. Patients older than 40 years, and probably also patients between 20 and 40 years, may benefit most from an autologous stem cell transplantation.


    • 1 August 2000
      • Vol. 72  (2) , 151-6

    Stem cell transplantation for patients with myelodysplastic syndrome and secondary leukemias.

    by T De Witte

    Most patients with myelodysplastic syndrome (MDS) are too old to be considered for intensive treatment, such as stem cell transplantation (SCT). Allogeneic SCT from an HLA-identical sibling donor is the curative treatment option for a relatively young patient (younger than 60 years) with MDS or secondary acute myeloid leukemia. Older age and lack of sibling donors limit this application. Alternative stem cell sources, such as unrelated donors, nonidentical family members, or autologous transplants, have been used more recently. Most patients may benefit optimally from an allogeneic SCT when the transplant is performed as soon as an HLA-identical family member has been identified. Progression to more advanced leukemia conditions will be associated with a higher failure rate due to increased relapse rate after SCT and higher treatment-related mortality. Delay of the transplant may be justified in a minority of patients with refractory anemia or refractory anemia with ringed sideroblasts without profound cytopenias or complex cytogenetic abnormalities and no need for erythrocyte transfusions. The present data from patients transplanted with sources of hematopoietic stem cells other than histocompatible sibling donors give an indication of the potential of other forms of transplantation. The disease-free survival of patients transplanted with histocompatible sibling donors was significantly better than the outcome of patients transplanted with other sources of stem cells. About one-third of the patients transplanted with stem cells from histocompatible siblings and about one-quarter of the patients with stem cells from other sources may be free of disease for 3 years or longer. The results of these treatment forms have improved considerably, but the continuing high treatment-related mortality warrants that these patients should be treated within investigational protocols.


    • 1 June 2000
      • Vol. 95  (11) , 3328-34

    Risk assessment in patients with Ph+ chronic myelogenous leukemia at first relapse after allogeneic stem cell transplant: an EBMT retrospective analysis. The Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

    by C Guglielmi, W Arcese, J Hermans, A Bacigalupo, G Bandini, D Bunjes, E Carreras, A Devergie, F Frassoni, J Goldman, et al.

    Patients with Ph+ chronic myelogenous leukemia who relapse after a first allogeneic stem cell transplant still have a possibility of long-term survival. To assess the value of the individual therapeutic options, the factors predicting outcome should be identified. We investigated data from 500 patients who relapsed before July 1996; follow-up was updated during 1998. The actuarial survival from relapse was 34.2% (95% confidence interval [CI]: 29. 9%-38.5%) at 5 years and 23.4% (95% CI: 18.9%-27.9%) at 10 years. Survival after relapse was significantly related to 5 factors: time from diagnosis to transplant (< 2 years vs >/= 2 years), disease phase at transplant (first chronic phase vs other), disease stage at relapse (cytogenetic or chronic phase vs advanced phase), time from transplant to relapse (< 1 year vs >/= 1 year), and donor type (HLA-identical sibling vs volunteer unrelated donor). The effects of individual adverse risk factors were cumulative: The probability of survival at 10 years decreased stepwise from 42% (0 factors), 32% (1 factor), 14% (2 factors), 3% (3 factors), to 0% (4 or 5 factors). Novel strategies for high-risk patients are warranted. We conclude that these 5 factors should be taken into account when comparing results of salvage therapies in patients with Ph+ chronic myeloid leukemia relapsing after allogeneic stem cell transplant.


    • 1 May 1999
      • Vol. 93  (9) , 2831-8

    Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study.

    by P Guardiola, J E Anderson, G Bandini, F Cervantes, V Runde, W Arcese, A Bacigalupo, D Przepiorka, M R O'Donnell, P Polchi, et al.

    Agnogenic myeloid metaplasia (AMM) is a chronic myeloproliferative disorder in which patients with poor prognostic features, receiving conventional treatments, have a median survival of less than 3 years. In this retrospective multicenter study, we analyze the results and try to define the indications for allogeneic stem cell transplantation in AMM. From January 1979 to November 1997, 55 patients with a median age of 42 years were transplanted from HLA-matched related (n = 49) or alternative (n = 6) donors for AMM. A multivariate analysis was conducted to identify factors associated with posttransplant outcome. The median posttransplant follow-up was 36 months (range, 6 to 223). The 5-year probability of survival was 47% +/- 8% for the overall group, and 54% +/- 8% for patients receiving an unmanipulated HLA-matched related transplant. The 1-year probability of transplant-related mortality was 27% +/- 6%. Hemoglobin level </=100 g/L and osteomyelosclerosis before transplant adversely affected the outcome. The probability of developing grade III-IV acute graft-versus-host disease (GVHD) was 33% +/- 8%. Sixteen of 45 patients developed extensive chronic GVHD. At last follow-up, 22 patients were in complete histohematologic remission. Treatment failure was observed in 13 cases. Age at transplant and karyotype were predictors of treatment failure. Allogeneic stem cell transplantation is an effective treatment leading to cure in a substantial number of patients with AMM. A better characterization of the variables affecting the posttransplant outcome should lead to a decreased transplant-related mortality and an improvement in these results.


    • 1 June 1998
      • p. S66-70

    A retrospective Dutch study comparing T cell-depleted allogeneic blood stem cell transplantation vs T cell-depleted allogeneic bone marrow transplantation.

    by J J Cornelissen, W E Fibbe, A V Schattenberg, E J Petersen, R Willemze, T J De Witte, B Löwenberg, L F Verdonck, A Vd Biezen, R Brand

    Retrospectively, a cohort of 43 hematological patients receiving an allogeneic T cell-depleted (TCD)-PBSCT between 1994 and 1997, was compared to a cohort of 435 patients, who received an allogeneic TCD-BMT between 1990 and 1996. Both cohorts were comparable with respect to diagnosis, risk status, age and sex. PB grafts contained four to five times more hematopoietic progenitor cells and T cells as compared to BM grafts. T cell depletion was performed by either elutriation, CD34 selection, E-rosetting, or Campath serotherapy. Conditioning was cyclophosphamide/TBI in the majority of patients of both cohorts. All patients received cyclosporin A as GVHD prophylaxis until day 90 post-transplant. Engraftment was significantly faster in the PBPCT cohort with a median time to neutrophil recovery (>0.5 x 10(9)/l) of 16 vs 21 days in the BMT cohort (P = 0.0009). Platelet recovery to 50 x 10(9)/l was 16 vs 34 days for the PB and BM cohort respectively (P < 0.0001). A median percentage of 76% of BMT patients recovered to 50 within 100 days post-BMT vs 91% of patients receiving a PB graft. The incidence of acute GVHD grades II, III and IV was similar in both cohorts. In contrast, the probability of developing chronic GVHD was 21% in the BM cohort vs 37% in the PB cohort. Relapse incidence was reduced in the PB cohort (9 vs 29%), while treatment-related mortality was not different for both cohorts. These favorable results require confirmation by a prospective randomized trial, which is currently being performed by several European centers.